http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020193520-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1870024223df71c715c62d0edd723acb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2e7fa9433e04fc27265b1d92b48e1d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2020-03-24^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a16cfd1300f8be17d187c16b800920 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9000fe48f10471744b581bdec6657ffe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf0045ebb94843321164dbb7fb2bc6d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e9fc329ec22c1f551a0f4696a3cc88e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1e1c2500d4946767dc7ddcea8685686 |
| publicationDate | 2020-10-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020193520-A1 |
| titleOfInvention | Treatment of taupathy disorders by targeting new tau species |
| abstract | The invention relates to a method of treatment of Tauopathy disorder using antibody that specifically binds news Tau species, especially Tau species starting from the methionine residue at position (11), said methionine being N-alpha acetylated (AcMet11-Tau). The invention also relates to an antibody that specifically binds this new tau species. Inventors have discovered that AcMet11-Tau is a pathological Tau species that is involved in Tau pathology development. Inventors have demonstrated the causal link between AcMet11-Tau species and Tau pathology by showing that brain expression of AcMet11-Tau species potentiate Tau pathology development in Thy-Tau Transgenic mice and is involved in pathological process, at least by accelerating Tau pathology. Inventors have also used passive immunization approach based on a specific monoclonal antibody (2H2D11) in order to demonstrate that the reduction/neutralization of this Tau species in the Thy-Tau22 transgenic model of Tau pathology lead to protective effect towards Tau pathology and associated memory deficits. Furthermore, the inventors subcloned 2C12 hybridoma and selected the 2C1C8, a further antibody against N-alpha-acetyl-Met11-Tau (AcMett11-Tau). They demonstrate that the 2C1C8 antibody displayed also specificity towards N-alpha-terminally acetylated methionine11 of Tau protein and labels neurons displaying neurofibrillary degeneration in the hippocampus of Thy-Tau22 transgenic mice. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11492393-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11643457-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11584791-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023041805-A1 |
| priorityDate | 2019-03-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 340 of 340.